#United States #San Francisco #Hagens Berman #Corcept Therapeutics #CORT

Corcept Therapeutics Faces Class Action Lawsuit

Corcept Therapeutics Incorporated (NASDAQ: CORT) is under scrutiny as a class action lawsuit raises serious allegations of misleading statements regarding its lead drug candidate, relacorilant. The law firm Hagens Berman is actively reminding investors about an important upcoming deadline concerning their rights in this situation.

Background of the Case

Hagens Berman, a prominent shareholder rights law firm, is urging investors who suffered significant financial losses in Corcept during the class period from October 31, 2024, to December 30, 2025, to take immediate action. The lawsuit, titled Allegheny County Employees' Retirement System v. Corcept Therapeutics Inc., et al., has been filed in the U.S. District Court for the Northern District of California.

The heart of the allegations lies in the claim that Corcept made materially false and misleading statements about its clinical drug development, particularly regarding the efficacy evidence for relacorilant necessary for New Drug Application (NDA) approval. Reed Kathrein, a partner at Hagens Berman leading the investigation, outlined that this case represents a significant 'information gap' between what the company publicly communicated and the private concerns expressed by the FDA during meetings.

Allegations of Misleading Statements

The claims against Corcept include:

• - Concealed FDA Concerns: Throughout the class period, numerous pre-submission meetings held in 2024 and early 2025 suggested that the FDA believed Corcept's clinical data lacked the necessary evidence of effectiveness to propose a favorable NDA.
• - Misleading Narrative: Despite knowing the FDA’s reservations, Corcept continued to promote positive Phase 3 results, ultimately presenting a narrative that may not have reflected the true status of their drug candidate.

This situation reached a critical point on December 31, 2025, when Corcept disclosed receiving a Complete Response Letter (CRL) from the FDA, indicating that it could not validate the drug’s benefit-risk assessment due to insufficient evidence. Following this disclosure, Corcept's stock plummeted from $70.20 to $34.80 per share within a day, wiping out nearly $2.5 billion in market capitalization.

Next Steps for Investors

Affected investors are encouraged to take action before the deadline of April 21, 2026, to potentially serve as Lead Plaintiff in the pending class action. This is an opportunity for those who purchased shares during the specified timeline to seek accountability regarding this situation. Investors can find detailed information and submit their claims on the Hagens Berman’s dedicated case page.

How to Get Involved

If you are a Corcept investor and would like to learn more about your rights or have questions regarding the class action, you can contact Reed Kathrein at Hagens Berman at 844-916-0895 or via email. The firm also invites whistleblowers to step forward, noting that under the SEC Whistleblower program, they may receive rewards for valuable insights that lead to successful recoveries.

Conclusion

The case against Corcept Therapeutics serves as a reminder to investors about the importance of transparency and accurate reporting by companies on matters concerning drug development and regulatory approvals. The outcome of this class action could not only impact the company but also set precedents for how pharmaceutical firms communicate with investors during critical junctures of drug approval processes.